Q-omics provides the consensus-scored PNPT1P1 profile across patient tissues and cancer cell-line models. PNPT1P1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, PNPT1P1 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, PNPT1P1 RNA expression shows 13,032 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LIHC, COAD, and THYM as cancer lineages where PNPT1P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PNPT1P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PNPT1P1 survival associations across molecular data types. PNPT1P1 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PNPT1P1 RNA expression–survival associations across cancer types. High PNPT1P1 expression shows unfavorable associations in LIHC, MESO, PCPG, LUSC and OV, but favorable associations in COAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for PNPT1P1 RNA expression.
This table summarizes PNPT1P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for PNPT1P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PNPT1P1 shows lower tumor expression in PAAD and READ and higher tumor expression in COAD, BLCA, STAD and PRAD. The COAD box plot shows higher PNPT1P1 RNA expression in tumor versus normal tissue (log2 FC = +0.121, t-test p < 0.001).
This table shows molecular features associated with PNPT1P1 in patient tissues and cancer cell lines. In patient samples, PNPT1P1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
